The Duke Division of Medical Oncology includes more than 50 full-time faculty and 21 hematology-oncology fellows, as well as a full team of nurse practitioners and physician assistants, registered nurses, and dedicated health care staff. Together we provide care to thousands of patients annually.
Duke is ranked as one of the top cancer hospitals in the country (#11) by U.S. News & World Report.
Firsts in Medical Oncology at Duke
- 1993: The Duke Comprehensive Cancer Center develops the nation's first outpatient bone-marrow transplantation program.
- 1994-1995: Duke scientists help discover the BRCA1 and BRCA2 genes responsible for many inherited forms of breast and ovarian cancers.
- 2003-2004: Duke is the lead center for a landmark national clinical trial that leads to Food and Drug Administration approval of bevacizumab, the first anti-angiogenesis drug proven to shrink tumors and extend survival in patients with metastatic colorectal cancer.